Investors & Media
Axovant Strengthens Executive Team with Key Management Appointments
"We are delighted to welcome this group of accomplished pharmaceutical and biotech leaders to Axovant," said
"I look forward to working alongside these impressive leaders," said
New Executive Team Members
Mr. Mohr joins Axovant with over 25 years of experience in pharmaceutical legal and compliance matters. He was previously U.S. General Counsel and Deputy General Counsel,
Dr. Floyd joins Axovant with nearly 20 years of regulatory experience within the pharmaceutical industry. Most recently, he was president of compliance services and chief scientific officer at
Dr. Templeman joins Axovant with over 25 years of experience across various aspects of pharmaceutical operations. He most recently served as chief operations officer at Graybug Vision, and was senior vice president of pharmaceutical operations and quality at Medivation prior to that. He previously held positions of increasing responsibility at
Mr. Wadley joins Axovant with 24 years of commercial leadership experience across sales, marketing, payer access and commercial operations. Mr. Wadley most recently served as senior vice president of sales at
Ms. Bari joins Axovant with over 25 years of U.S. and global communications experience in the healthcare and pharmaceutical industries. Most recently, she was vice president of corporate communications at Medivation, and was senior vice president of corporate communications at Pharmacyclics prior to that. She has also held positions of increasing responsibility at Ikaria,
In addition, current executive team member Dr. Shankar Ramaswamy will take on a new role at Axovant as vice president, global medical affairs. Dr. Ramaswamy was one of the earliest employees of Axovant and has served the company in multiple roles, including most recently as vice president, medical and scientific communications. He was also involved in the scientific evaluation of new assets for Axovant. Dr. Ramaswamy holds an A.B. from
Additional New Hires
Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant is developing a pipeline of late- and early-stage product candidates that focuses on the cognitive, functional, and behavioral aspects of debilitating conditions such as Alzheimer's disease and Lewy body dementia and other neurological disorders. For more information, visit www.axovant.com.
This press release contains forward-looking statements, including statements regarding Axovant's clinical development and regulatory strategy for intepirdine and nelotanserin. Forward-looking statements can be identified by the words "believe," "anticipate," "continue," "estimate," "project," "expect," "plan," "potential," "intend," "will," "would," "could," "should" or the negative or plural of these words or other similar expressions that are predictions or indicate future events, trends or prospects.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of intepirdine and nelotanserin; and increased regulatory requirements. These statements are subject to the risk that clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share Axovant's views of the clinical study data. In addition, promising interim results or other preliminary analyses do not in any way ensure that later or final results in a clinical trial or in related or similar clinical trials will replicate those interim results. The product discussed is investigational and not approved and there can be no assurance that the clinical program for intepirdine or nelotanserin will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that any of our product candidates will ever receive regulatory approval or be successfully commercialized.
For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant's business in general, see the "Risk Factors" section of our quarterly report on Form 10-Q filed with the
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-strengthens-executive-team-with-key-management-appointments-300469322.html
Investors, Jonathan Neely, (212) 634-9744, firstname.lastname@example.org, or Media, Brian Reid, (212) 257-6725, email@example.com